It is early 2001 and drugs company has just received FDA approval to market Angiomax, a blood thinner that will be used during angioplasty and heart procedures. It is designed to be the best alternative to heparin, 80-year-old drug that costs less than $ 10 per dose. The Company believes that it can sell Angiomax at a much higher price than the heparin - but how much more? Angiomax is also the first of several drugs developed under a rather unique business model. The company is in the business of "saving" drugs that other companies have abandoned - that is, they buy a license or rights to drugs that other companies to stop development, with the intent to complete the development and attraction of drugs on the market. With the success of Angiomax, the Company believes that this business model has been confirmed.
This case is only available in paper format (HBP do not have the rights to distribute digital content). As a result, a digital copy of an educator if not available through this Web site. "Hide
by John T. Gourville Source: HBS Premier Case Collection 18 pages. Publication Date: July 3, 2001. Prod. #: 502006-PDF-ENG
Related Case Solutions & Analyses:
Cocoa Petes Chocolate Adventures (Abridged)
Note on the FDReview Process for Medical Devices
Jane Lennox
A Tale of Two Turnarounds at EDS: The Jordan Rules
Baltic Beverages Holding: Competing in a Globalizing World (A)
IDEO PRODUCT DEVELOPMENT
Strategic audit of Sony Corporation
Philip Morris- Project Valuation
Disturbed Sensory (Auditory) Perception
Culture – USA
